Q-Line Biotech Reports Significant Profitability Surge in FY26; Revenue Up 9.13%

Q-Line Biotech Reports Significant Profitability Surge in FY26; Revenue Up 9.13%​

Q-Line Biotech Limited, a major manufacturer of diagnostic test kits and laboratory equipment, has reported audited financial results for the half year and full year ended March 31, 2026. The company saw substantial growth in profitability, with Profit After Tax (PAT) surging by 56.75% Year-on-Year (Y-o-Y).

The Board of Directors approved the results at its meeting on June 17, 2026. Q-Line Biotech serves diagnostic laboratories and hospitals across 26 states from its headquarters in Lucknow, driven by sustained product demand and market expansion efforts.

Financial Performance Overview​

The company's financial performance showed strong momentum throughout FY26. Key highlights comparing the current fiscal year (FY26) against the previous year (FY25) include:

• Total Revenue: Grew 9.13% Y-o-Y, reaching ₹ 341.73 crore.
• EBITDA: Expanded by 38.97% Y-o-Y, reaching ₹ 98.04 crore. The company’s EBITDA margin strengthened to 28.69%, up from 22.53% in FY25.
• Profit Before Tax (PBT): Surged by 42.23% Y-o-Y, demonstrating operational leverage.
• Profit After Tax (PAT): Showed a marked increase of 56.75% Y-o-Y, achieving ₹ 56.71 crore.

The company noted that reagents and diagnostic kits constitute approximately 69% of its total revenue, providing a stable base due to their consumable nature and regular demand from healthcare institutions. The significant margin improvement is attributed primarily to nearly 70% growth in the sales of domestically manufactured reagents, alongside improved operating efficiencies and disciplined cost management.

Momentum in Half Year FY26​

Performance accelerated notably in H2 FY26 (the latter half of the fiscal year). Revenue increased by 37.65% compared to H1 FY26, reaching ₹ 197.93 crore. EBITDA improved by 72.6% over H1 FY26, while PBT surged by 80.2%. PAT saw a rise of 66.06% H-o-H, reaching ₹ 35.40 crore.

Strategic and Business Developments​

Q-Line Biotech continues to invest heavily in manufacturing expansion and strategic international growth:

• Manufacturing Expansion: The company secured product licenses for five items at its new Unit 4 manufacturing facility, with additional licenses pending approval. Full-scale commercial production of Clinical Chemistry Reagents is planned by Q2 FY27 upon regulatory approvals.
• Digital Transformation: A new ERP platform implementation has commenced to enhance operational controls and data-driven decision-making, with full rollout targeted for the end of FY27.
• Governance and Controls: PwC has been engaged to assist in strengthening Internal Financial Controls (IFC) and Internal Controls over Financial Reporting (ICFR) to support the company's growth as a listed entity.
• International Expansion: An International Business Manager was appointed in Dubai to accelerate business development. This expansion led to approximately ₹ 1.18 Cr in export sales for the year. The company has established distributor agreements across 7 or 8 countries as of March 2026, aiming for export revenues to grow nearly 5X in FY27.
• Technology Collaboration: The company holds exclusive technical collaboration agreements with Vital Scientific and Boule Sweden AB for the manufacturing and commercialization of certain instruments and reagents intended for Indian markets. Furthermore, it plans to initiate CDMO operations by exporting Selectra Pro M and Microlab 300 instruments to the principal company in exchange for leveraging its manufacturing capabilities globally.

Management Commentary​

Saurabh Garg, Managing Director and Chairman of Q-Line Biotech, commented that FY26 was transformative, noting that successful capitalization of their largest manufacturing facility significantly strengthens operational capabilities. He highlighted that sales of manufactured reagents increased by nearly 70%, reflecting the strategic focus on expanding in-house production and reducing dependence on traded products.

Regarding instruments, Garg noted that the company has reached an installed base of over 1,550 Selectra Pro M Fully Automatic Biochemistry Analysers. Furthermore, following the commercialization of their Electrolyte Analyzer, the Micro lab 300 is slated for launch by Q2 FY27.

Financial Guidance and Future Outlook (FY27)​

Q-Line Biotech provided guidance for FY27, targeting a revenue growth range of approximately 30 to 35% Y-o-Y, with corresponding EBITDA margin targets in place. IPO proceeds are earmarked to fund working capital requirements, which will be used to expand the sales force and increase instrument installed bases. CDMO and export operations are expected to contribute substantially to overall revenue expansion in FY27.

QLINE Stock Price Movement​

Q-Line Biotech Limited shares gained 3.11% in post-market trading today, closing at ₹525.85 as the stock traded significantly higher. The equity notably reached its 52-week high when it settled, and a volume of 403,200 shares was recorded during the session.